Double high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation for primary disseminated medulloblastoma: a report of 3 cases

J Pediatr Hematol Oncol. 2010 Mar;32(2):e70-4. doi: 10.1097/MPH.0b013e3181c46b92.

Abstract

We performed double high-dose chemotherapy followed by peripheral blood stem cell transplantation (PBSCT) in 3 children with medulloblastoma and primary leptomeningial dissemination, including spinal metastasis. After resection of the main tumor mass, 30.6 Gy whole craniospinal radiation therapy and 4 or 5 courses of conventional chemotherapy with vincristine (1.5 mg/m), carboplatin (560 mg/m), ifosfamide (9000 mg/m), and etoposide (500 mg/m), and 2 courses of high-dose thiotepa (680 mg/m) and melphalan (240 mg/m) therapy with PBSCT were administered. Two patients with low erythroblastic leukemia viral oncogene homolog 2 (ERBB2) gene expression achieved long-term survival (41 mo and 40 mo) but the patient with high ERBB2 expression relapsed 9 months after the second PBSCT.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cerebellar Neoplasms / pathology
  • Cerebellar Neoplasms / therapy*
  • Child
  • Combined Modality Therapy
  • Humans
  • Male
  • Medulloblastoma / pathology
  • Medulloblastoma / therapy*
  • Peripheral Blood Stem Cell Transplantation* / adverse effects
  • Receptor, ErbB-2 / analysis
  • Transplantation, Autologous

Substances

  • ERBB2 protein, human
  • Receptor, ErbB-2